Last updated: February 25, 2026
What is the drug with NDC 70000-0659?
The NDC 70000-0659 corresponds to Ado-Trastuzumab Emtansine (Kadcyla). It is an antibody-drug conjugate used primarily for HER2-positive breast cancer therapy.
Market Overview
Indications and Utilization
- Approved for metastatic HER2-positive breast cancer following trastuzumab and chemotherapy.
- Also approved for adjuvant treatment of HER2-positive early breast cancer in certain contexts between 2019 and 2021.
Competitive Landscape
- Major competitors include trastuzumab (Herceptin), trastuzumab deruxtecan (Enhertu), and other HER2-directed therapies.
- The market is largely driven by breast cancer prevalence, with an estimated 1.7 million new cases annually worldwide.[1]
Market Size
- Estimated global breast cancer drug market size: USD 15.2 billion in 2022.
- HER2-positive segment accounts for approximately 20% of breast cancer cases (~340,000 cases annually).
Usage Trends
- Monotherapy in metastatic settings.
- Combination with chemotherapy in adjuvant settings.
- Growing use in early-stage breast cancer, expanding the patient population.
Price Structure and Historical Pricing
Past Pricing Data
- List price of Kadcyla (as of 2022): approximately USD 9,800 per 100 mg vial.
- Typical treatment course involves 2.4 mg/kg every 3 weeks, with average treatment cost per patient reaching USD 60,000–USD 100,000.
Reimbursement and Pricing Policies
- Under Medicare Part B in the United States, reimbursed via average sales price (ASP) + 6%.
- Prices vary globally; European prices range from €6,000 to €12,000 per cycle.
Price Projections
Short-term (Next 1-2 Years)
- Anticipate slight price stabilization due to current manufacturing costs and reimbursement policies.
- No significant price reductions expected unless biosimilar entry occurs.
Medium to Long-term (3-5 Years)
- Possible price reduction of 10-15% with increased generic or biosimilar competition anticipated post-patent expiry, expected around 2027.
- Potential for value-based pricing models, especially if new indications are approved or if efficacy data improves.
Factors Affecting Future Pricing
- Patent Expiry: Patent protection expires in 2027, opening the market for biosimilar competitors.
- Regulatory Approvals: Additional indications could sustain demand and support premium pricing.
- Market Competition: Entry of biosimilars or competing therapies could drive prices downward.
- Manufacturing Costs: Advances in biosimilar manufacturing may reduce costs.
- Reimbursement Policies: Shifts towards value-based arrangements or budget caps could impact pricing.
Comparative Biosimilar Pricing (Projected)
- Biosimilar trastuzumab prices: 20-30% below original branded prices.
- Biosimilar conjugates like T-DM1 (Kadcyla) could see similar or slightly higher discounts, depending on market uptake and regulatory environment.
Key Takeaways
- NDC 70000-0659 (Kadcyla) has a significant market share in HER2-positive breast cancer.
- Current pricing ranges between USD 60,000–USD 100,000 per treatment course.
- The expiration of patent protection in 2027 is set to introduce biosimilar competition, likely reducing prices.
- Market growth remains strong due to expanding indications and increasing global breast cancer prevalence.
- Reimbursement policies continue to influence pricing stability in major markets.
FAQs
1. When will biosimilars for Kadcyla likely enter the market?
Biosimilar development typically follows 8-10 years after original approval; with Kadcyla approved in 2013, biosimilar candidates could enter as early as 2025–2027.
2. How much could biosimilar competition reduce prices?
Prices could decline by 20-30% relative to the branded product, depending on regulatory approval, market uptake, and coverage policies.
3. What are the main factors driving growth in Kadcyla’s market?
Expansion of indications, increased adoption in early breast cancer, and rising breast cancer incidence globally.
4. Are there any recent approvals that could influence price or demand?
Yes, in 2021, the FDA approved Kadcyla for adjuvant treatment in early-stage HER2-positive breast cancer, expanding potential patient population.
5. What is the overall revenue forecast for Kadcyla over the next five years?
Stable revenue growth is expected until patent expiry, with an estimated peak of USD 2.5 billion annually, followed by potential declines due to biosimilar entry.
References
[1] American Cancer Society. (2022). Breast Cancer Facts & Figures 2022. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html
[2] IQVIA. (2022). Global Oncology Market Report.
[3] U.S. Food and Drug Administration. (2013). Kadcyla (ado-trastuzumab emtansine) approval notice.
[4] European Medicines Agency. (2021). Kadcyla approval details.
